Flexible Dosing with Apidra®
Apidra®: rapid-acting insulin with Flexibility
for different eating schedules
Apidra® offers greater flexibility with premeal and
postmeal dosing
Effective glycemic control when taken either premeal or postmeal1,2
Premeal/postmeal study (N=860)1,2
Greater flexibility in time to inject
Regular
human insulin
premeal |
Apidra®
premeal |
Apidra®
postmeal |
A 12-week, randomized, 3-arm, open-label, active-control study in type 1 patients compared Apidra
® given premeal or postmeal with RHI given premeal (all groups were given long-acting basal insulin once daily; mean BMI 27.1 kg/m²). “Endpoint”was thelast available measurement after start of treatment.
¹,²
- Apidra® insulin given premeal or postmeal showed significant A1C reductions from baseline comparable to RHI given premeal2
- — As effective as RHI given 30 to 45 minutes premeal
- Administer Apidra® within 15 minutes before or within 20 minutes after starting a meal2
IMPORTANT SAFETY INFORMATION FOR APIDRA®
Apidra® is a rapid-acting human insulin analog indicated to improve
glycemic control in adults with type 2 diabetes or adults and children (4 years
and older) with type 1 diabetes. Apidra® is contraindicated during
episodes of hypoglycemia and in patients hypersensitive to Apidra®
or any of its excipients. Apidra® should normally be used in regimens
that include a longer-acting insulin.
OptiClik® is a reusable insulin delivery device for use with a 3-mL
Apidra® cartridge (U-100).
Needles, OptiClik® and cartridge systems must not be shared.
Apidra® has a more rapid onset and shorter duration of action than
regular human insulin. When used as a mealtime insulin, the dose of Apidra®
should be given within 15 minutes before or within 20 minutes after starting a meal.
Glucose monitoring is essential for patients receiving insulin therapy. Any change
in insulin and/or regimen should be made cautiously, only under medical supervision,
and may require a change in dose. Concomitant oral antidiabetic treatment may need
to be adjusted. As with all insulin preparations, the time course of Apidra®
action may vary by individual or at different times in the same individual and depends
on injection site, blood supply, temperature, and level of physical activity.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra®.
The timing of hypoglycemia usually reflects the time-action profile of the administered
insulin formulations. Other adverse events associated with Apidra®
include hypokalemia, allergic reactions, injection site reactions, lipodystrophy,
pruritus, and rash. Less common, but potentially more serious or life-threatening,
is generalized allergy to insulin, including anaphylactic reactions.
Apidra® should not be
mixed with other insulins or with a diluent when used in the pump.
Please click here for full prescribing information for Apidra®
